Results 121 to 130 of about 38,769 (305)
iNew Medicine, EarlyView.ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little +12 more
wiley +1 more source
LifeThe prevalence of hepatocellular carcinoma (HCC) has increased in recent years and resulted in many deaths, which necessitates new therapeutic solutions.
Hsien-Hui Chung
doaj +1 more source
SGLT2 inhibitors: expanding their Empire beyond diabetes [PDF]
The Lancet Diabetes & Endocrinology, 2021 Muskiet, Marcel H. A. +2 more
openaire +2 more sources
SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms [PDF]
Sodium-glucose cotransporter-2 (SGLT2) inhibitors afford significant cardiovascular benefits to patients with diabetes mellitus and heart failure. Three large randomized clinical trials (EMPAREG-Outcomes, DECLARE-TIMI58, and DAPA-HF) have shown that ...
Rong Zhou, Ya-ru Chen, Fang-yuan Zhu
core +1 more source
Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities
ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley +1 more source
Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI
iNew Medicine, EarlyView.Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang +9 more
wiley +1 more source
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
A growing body of evidence indicates that nonglycemic effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors play an important role in the protective effects of these drugs in diabetes, chronic kidney disease, and heart failure.
Elena Y. Rykova +5 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala +1 more
wiley +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐
Jiunn‐Jye Sheu +6 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source